129 related articles for article (PubMed ID: 32521942)
1. Duration of trastuzumab maintenance in HER2-positive metastatic breast cancer patients with radiological complete remission: Robust predictive markers are needed!
Altundag K
J BUON; 2020; 25(2):1269. PubMed ID: 32521942
[No Abstract] [Full Text] [Related]
2. Trastuzumab-emtansine might affect the survival outcome by reversing increased platelet-to-lymphocyte ratio in HER2-positive metastatic breast cancer patients.
Altundag K
J BUON; 2019; 24(1):407. PubMed ID: 30942001
[No Abstract] [Full Text] [Related]
3. Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?
Steenbruggen TG; Bouwer NI; Smorenburg CH; Rier HN; Jager A; Beelen K; Ten Tije AJ; de Jong PC; Drooger JC; Holterhues C; Kitzen JJEM; Levin M-; Sonke GS
Breast Cancer Res Treat; 2019 Dec; 178(3):597-605. PubMed ID: 31493033
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence?
Ricci F; Le Tourneau C
Chin Clin Oncol; 2018 Feb; 7(1):3. PubMed ID: 29156892
[No Abstract] [Full Text] [Related]
5. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
Chumsri S; Sperinde J; Liu H; Gligorov J; Spano JP; Antoine M; Moreno Aspitia A; Tan W; Winslow J; Petropoulos CJ; Chenna A; Bates M; Weidler JM; Huang W; Dueck A; Perez EA
Clin Cancer Res; 2018 Jul; 24(13):3053-3058. PubMed ID: 29530935
[No Abstract] [Full Text] [Related]
6. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
[TBL] [Abstract][Full Text] [Related]
7. Exceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer.
Li A; Goodyear S; Fuss C; Mitri Z
JCO Precis Oncol; 2021 Nov; 5():904-909. PubMed ID: 34994619
[No Abstract] [Full Text] [Related]
8. Efficacy of Adjuvant Combination Therapy With Trastuzumab and Chemotherapy in HER2-positive Early Breast Cancer: A Single Institutional Cohort Study from Clinical Practice.
Okamoto M; Tajiri W; Ueo H; Masuda T; Ijichi H; Koga C; Nakamura Y; Taguchi K; Ohno S; Tokunaga E
Anticancer Res; 2020 Jun; 40(6):3315-3323. PubMed ID: 32487627
[TBL] [Abstract][Full Text] [Related]
9. Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?
Fabi A; Giannarelli D; Moscetti L; Santini D; Zambelli A; Laurentiis M; Caruso M; Generali D; Valle E; Leonardi V; Cannita K; Arpino G; Filippelli G; Ferretti G; Giampaglia M; Montemurro F; Nisticò C; Gasparro S; Cognetti F
Future Oncol; 2017 Dec; 13(30):2791-2797. PubMed ID: 29182361
[TBL] [Abstract][Full Text] [Related]
10. tRNA-Derived Fragments as Novel Predictive Biomarkers for Trastuzumab-Resistant Breast Cancer.
Sun C; Yang F; Zhang Y; Chu J; Wang J; Wang Y; Zhang Y; Li J; Li Y; Fan R; Li W; Huang X; Wu H; Fu Z; Jiang Z; Yin Y
Cell Physiol Biochem; 2018; 49(2):419-431. PubMed ID: 30153663
[TBL] [Abstract][Full Text] [Related]
11. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
[TBL] [Abstract][Full Text] [Related]
13. A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer.
Dent S; Ammendolea C; Christofides A; Edwards S; Incekol D; Pourmirza B; Kfoury S; Poirier B
Curr Oncol; 2019 Feb; 26(1):e70-e80. PubMed ID: 30853812
[TBL] [Abstract][Full Text] [Related]
14. Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer.
Parmar S; Keck JM; Kong B; Look R; Johnson B; Patterson J; Labrie M; Guimaraes AR; Corless CL; Beadling C; Kolodzie A; Bergan R; Gray JW; Mills GB; Mitri ZI
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250408
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.
Chen S; Liang Y; Feng Z; Wang M
BMC Cancer; 2019 Oct; 19(1):973. PubMed ID: 31638935
[TBL] [Abstract][Full Text] [Related]
16. The use of trastuzumab in New Zealand women with breast cancer.
Lawrenson R; Lao C; Campbell I; Harvey V; Brown C; Seneviratne S; Edwards M; Elwood M; Kuper-Hommel M
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e152-e160. PubMed ID: 28856817
[TBL] [Abstract][Full Text] [Related]
17. Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer.
Kurozumi S; Inoue K; Matsumoto H; Fujii T; Horiguchi J; Oyama T; Kurosumi M; Shirabe K
Sci Rep; 2019 Feb; 9(1):1583. PubMed ID: 30733496
[TBL] [Abstract][Full Text] [Related]
18. Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis.
Park WY; Kim HJ; Kim K; Bae SB; Lee N; Lee KT; Won JH; Park HS; Lee SC
Cancer Res Treat; 2016 Apr; 48(2):843-7. PubMed ID: 25761487
[TBL] [Abstract][Full Text] [Related]
19. Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy.
Ding N; Huang J; Li N; Yuan J; Wang S; Xiao Z
BMC Cancer; 2020 Mar; 20(1):235. PubMed ID: 32192443
[TBL] [Abstract][Full Text] [Related]
20. New insights into affinity proteins for HER2-targeted therapy: Beyond trastuzumab.
Akbari V; Chou CP; Abedi D
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188448. PubMed ID: 33039514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]